Commentary
Renin–angiotensin–aldosterone system inhibitors and COVID-19
Kieran L. Quinn, Michael Fralick, Jonathan S. Zipursky and Nathan M. Stall
CMAJ May 19, 2020 192 (20) E553-E554; DOI: https://doi.org/10.1503/cmaj.200619
Kieran L. Quinn
Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
MD MScMichael Fralick
Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
MD PhDJonathan S. Zipursky
Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
MDNathan M. Stall
Department of Medicine (Quinn, Fralick, Zipursky, Stall), University of Toronto; Division of General Internal Medicine and Geriatrics (Quinn, Fralick, Stall), Sinai Health System; Institute of Health Policy, Management and Evaluation (Quinn, Zipursky, Stall), University of Toronto; Division of Clinical Pharmacology and Toxicology (Zipursky), Sunnybrook Health Sciences Centre, Toronto, Ont.
MD![Loading Loading](https://www.cmaj.ca/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
Renin–angiotensin–aldosterone system inhibitors and COVID-19
Kieran L. Quinn, Michael Fralick, Jonathan S. Zipursky, Nathan M. Stall
CMAJ May 2020, 192 (20) E553-E554; DOI: 10.1503/cmaj.200619
Related Articles
Cited By...
- Effect of Renin-Angiotensin-Aldosterone System inhibitors on outcomes of COVID-19 patients with hypertension: Systematic review and Meta-analysis
- Further developments in the literature on RAAS inhibitors and COVID-19
- Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?
- Association between angiotensin blockade and COVID-19 severity in Hong Kong
- Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19